HOME >> BIOLOGY >> NEWS
Physicists use fractals to help Parkinson's sufferers

A new portable system for analyzing the walking patterns of people with Parkinson's disease has been developed by researchers in the US and Japan. The system, described in the Institute of Physics publication Journal of Neural Engineering, will help doctors monitor the progress of the disease in patients and so tailor their therapy and drug regime more accurately than previously possible.

Parkinson's disease is a progressive disorder of the central nervous system. Its symptoms include: uncontrollable trembling, difficulty walking, and postural problems that often lead to falls. These symptoms are usually controlled with dopamine agonist drugs. However, these can have a number of side-effects, such as jerking movements. It is also known that the body builds up a tolerance to the drug.

Understanding the nature and severity of symptoms for individual patients, which is reflected in their walking pattern, could help doctors improve a patient's quality of life, by guiding their treatment more effectively, and so reduce side-effects.

Researchers have previously tried to quantify the problems suffered by Parkinson's patients by studying their gait. Now, Masaki Sekine, Metin Akay, and Toshiyo Tamura, of the Department of Gerontechnology, National Institute for Longevity Sciences, in Aichi, Japan and Thayer School of Engineering, New Hampshire USA, working with their colleagues at the Fujimoto Hayasuzu Hospital, in Miy azaki, Japan, have devised a portable system based on a sensor placed on the patient's body that measures movements in three dimensions. The readings from this sensor, known as a tri-axial accelerometer, are fed to a computer, together with measurements of the patients walking speed, and analysed using a fractal system.

Fractals are usually associated with irregular geometric objects that look the same no matter what scale they are viewed at: clouds, branching trees, rugged coastlines, rocky mountains, are all examples of fracta
'"/>

Contact: David Reid
david.reid@iop.org
207-470-4815
Institute of Physics
2-Feb-2004


Page: 1 2

Related biology news :

1. Physicists reveal first nanoflowers
2. Physicists Find Simple Solution To Great-And-Small Mystery
3. TANGO: towards faster prognosis of Alzheimers and Parkinsons diseases?
4. New genetic research demonstrates possible cause of inherited form of Parkinsons disease
5. Study sheds new light on genetic risk for Parkinsons disease
6. Single gene mutation muddying Parkinsons risk forecasts
7. Ritalin may improve Parkinsons symptoms, OHSU study says
8. Parkinsons disease genetic study progresses with $8 million grant
9. PDF invites scientists pursuing Parkinsons research to apply for funding
10. Yeast model yields insights into Parkinsons disease
11. Yeast helps researchers better understand Parkinsons mystery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Physicists use fractals help Parkinson sufferers

(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: